Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
UroGen Pharma Ltd. - Ordinary Shares
(NQ:
URGN
)
41.40
+0.85 (+2.10%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about UroGen Pharma Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at Upcoming Investor Conferences
September 02, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
August 20, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
August 17, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
August 05, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
July 29, 2026
Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
July 15, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
July 08, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 05, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
June 02, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
June 01, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
May 15, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
May 13, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at Upcoming Investor Conferences
May 07, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
May 06, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
April 29, 2026
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET
From
UroGen Pharma Ltd.
Via
GlobeNewswire
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
March 30, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
March 13, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
March 02, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
March 02, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
February 27, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
February 23, 2026
Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ET
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
February 04, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
January 05, 2026
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
November 06, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
November 06, 2025
From
UroGen Pharma Ltd.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
